Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.3K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.3K
iPS Cell Differentiation01:22

iPS Cell Differentiation

2.8K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.8K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

529
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
529

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and Feasibility of Immunoadsorption with Heparin Anticoagulation in Preparation of ABO-Incompatible Kidney Transplantation: A Retrospective Single-Center Study.

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie·2023
Same author

Characterization of pathogen-inactivated COVID-19 convalescent plasma and responses in transfused patients.

Transfusion·2022
Same author

Daratumumab for immune thrombotic thrombocytopenic purpura.

Blood advances·2021
Same author

International Forum on Transfusion Practices in Haematopoietic Stem-Cell Transplantation: Summary.

Vox sanguinis·2021
Same author

International Forum on Transfusion Practices in Haematopoietic Stem-Cell Transplantation: Responses.

Vox sanguinis·2021
Same author

Extracorporeal Photopheresis in Graft-versus-Host Disease.

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie·2020

Related Experiment Video

Updated: Sep 30, 2025

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.9K

[Future perspectives in Myelodysplastic Syndrome].

Gregor Stehle1

  • 1Zentrum für Stammzellentransplantation, Hämatologie, Universitätsspital Basel.

Therapeutische Umschau. Revue Therapeutique
|March 16, 2022
PubMed
Summary

Molecular genetics will advance the diagnosis, prognosis, and therapy of Myelodysplastic Syndromes (MDS). New treatments and combination therapies offer hope for high-risk MDS, while anemia remains a challenge in low-risk cases.

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Myelodysplastic Syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
  • Anemia presents a significant therapeutic challenge in low-risk MDS.
  • High-risk MDS requires novel therapeutic strategies.

Purpose of the Study:

  • To outline future perspectives in the diagnosis, prognosis, and therapy of Myelodysplastic Syndromes.
  • To highlight advancements in molecular genetics for MDS management.
  • To discuss emerging treatment options for different risk strata of MDS.

Main Methods:

  • Review of current literature and emerging trends in MDS research.
  • Analysis of the evolving role of molecular genetics in clinical practice.

More Related Videos

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.4K
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

11.8K

Related Experiment Videos

Last Updated: Sep 30, 2025

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.9K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.4K
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

11.8K
  • Evaluation of new therapeutic agents and combination strategies.

    • Main Results:

    • Molecular genetics is expected to play an increasingly significant role in MDS diagnosis, prognosis, and therapy.
    • Novel drugs are emerging for high-risk MDS, enabling combination therapies.
    • Addressing anemia in low-risk MDS remains a critical clinical challenge.

    Conclusions:

    • The integration of molecular genetics will personalize MDS treatment.
    • Advancements in therapeutics offer improved outcomes for high-risk MDS patients.
    • Patient participation in clinical studies is crucial for advancing MDS care.